Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of setmelanotide in rare genetic obesity disorders
MOH_2021-08-10_010198Phase 3Active, not recruiting
- Sponsor
- Rhythm Pharmaceuticals
- Start
- Aug 2021
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of setmelanotide in No canonical full name exists for "genetic obesity.", sponsored by Rhythm Pharmaceuticals. Primary endpoint: Safety and tolerability of continued setmelanotide treatment. Started Aug 2021; status: active, not recruiting.
02
Drugs
setmelanotide
03
Conditions
No canonical full name exists for "genetic obesity."
Beyond the preview
Go deeper on MOH_2021-08-10_010198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-08-10_010198.